Novo Nordisk v. Alvogen: 10-Patent Ozempic Dispute Ends in Stipulated Dismissal
Novo Nordisk filed suit against Alvogen in Delaware in March 2022, asserting 10 patents protecting its blockbuster GLP-1 drug Ozempic (semaglutide) against a prospective generic entrant. After 677 days of litigation, the parties jointly stipulated to dismissal in January 2024 — before any trial on the merits.
10-patent Ozempic defence resolved by stipulation before trial
On 4 March 2022, Novo Nordisk A/S filed a patent infringement action against Alvogen Group, Inc. in the U.S. District Court for Delaware (Case No. 1:22-cv-00299) before Chief Judge Colm F. Connolly. The suit asserted ten patents — spanning formulation, device, and method claims — covering Ozempic® (semaglutide) subcutaneous solution at concentrations of 1.34 mg/ml in both 2 mg/1.5 ml and 4 mg/3 ml presentations. The filing is consistent with a standard Paragraph IV ANDA litigation pattern, in which a branded manufacturer seeks to block a generic applicant from entering the market before patent expiry.
The case closed on 10 January 2024 — 677 days after filing — by way of a Stipulation and Order of Dismissal. The public record identifies the basis of termination simply as ‘Case Dismissed’, without specifying whether the dismissal was with or without prejudice. Stipulated dismissals of this type are a common endpoint in Hatch-Waxman ANDA litigation, and may reflect negotiated resolution, a licensing arrangement, a consent judgment, or a commercial settlement — none of which are confirmed by the available public docket.
Resolution before trial in a ten-patent ANDA matter is notable: cases asserting this volume of patents frequently proceed through claim construction and often to bench trial. The relatively contained timeline — under two years — suggests either focused early motion practice, a negotiated agreement, or a commercial resolution that made continued litigation unnecessary. What drove the stipulation, and whether Alvogen retains any right to re-enter the semaglutide market on defined terms, is not disclosed in publicly available records.
Filing to dismissal in 677 days
677 days from filing to stipulated dismissal — shorter than many ANDA patent trials
What the stipulated dismissal means for Novo Nordisk and Alvogen
Stipulated dismissal: a mutual agreement to end the case
A stipulated dismissal means both parties jointly asked the court to close the case — the court itself did not rule on infringement or validity. In Hatch-Waxman ANDA litigation, this outcome typically signals a negotiated resolution rather than a unilateral withdrawal. The underlying terms — whether a licence, a consent judgment, or a market-entry agreement — are not disclosed in the public docket for this matter.
No merits ruling on infringementWith or without prejudice? The public record is silent
A dismissal ‘with prejudice’ bars the plaintiff from refiling the same claims; a dismissal ‘without prejudice’ preserves that right. The stipulation in this case does not specify which applies, so no inference can be drawn. In practice, parties negotiating ANDA settlements frequently agree to a dismissal that is functionally final — often paired with a licence — but the terms are typically kept confidential. The public record does not confirm either scenario here.
Prejudice status undisclosedTen patents — a broad, layered IP defence for Ozempic
Novo Nordisk asserted ten patents across multiple patent families, covering aspects ranging from the semaglutide compound and formulation to delivery device design and method of use. This multi-patent strategy is standard practice in blockbuster ANDA defence: it forces the generic challenger to invalidate or design around every asserted claim, raising litigation cost and complexity. The breadth of the portfolio likely shaped Alvogen’s calculus on whether to proceed to trial.
10 patents, multiple claim typesOzempic’s commercial scale raised the stakes for both sides
Ozempic (semaglutide) is one of the highest-revenue pharmaceutical products globally, with annual sales in the billions. For Novo Nordisk, even a brief period of generic competition could represent enormous lost revenue. For Alvogen, a favourable resolution — whether a licence or a settlement with a defined entry date — could represent a commercially significant generic opportunity. The high stakes on both sides are consistent with a negotiated outcome rather than a litigated decision.
Multi-billion dollar marketFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novo Nordisk A/S | Company | Danish pharmaceutical innovator — holder of 10 patents covering Ozempic (semaglutide)Search in Eureka ↗ |
| Defendant | Alvogen Group, Inc. | Company | Alvogen Group, Inc. — specialty generic pharmaceutical company seeking ANDA market entrySearch in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Defendant counsel | Chantelle D. Ankerman | Attorney | Counsel for Alvogen Group, Inc.Search in Eureka ↗ |
| Defendant counsel | Emily DiBenedetto | Attorney | Counsel for Alvogen Group, Inc.Search in Eureka ↗ |
| Defendant counsel | Joshua S. Reisberg | Attorney | Counsel for Alvogen Group, Inc.Search in Eureka ↗ |
| Defendant counsel | Karen Elizabeth Keller | Attorney | Counsel for Alvogen Group, Inc.Search in Eureka ↗ |
| Defendant counsel | Matthew J. Becker | Attorney | Counsel for Alvogen Group, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Chief Judge | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The Stipulation and Order of Dismissal reflects a consensual termination agreed by both parties — not a judicial determination of infringement or patent validity. The court’s role was limited to so-ordering the parties’ agreement. This means the patents-in-suit (all ten) remain nominally intact in terms of validity as a matter of public record; no claim was held invalid or not infringed. The substantive IP questions raised by Alvogen’s ANDA filing are unresolved on the public docket, and the commercial terms of any underlying arrangement remain confidential.
US8129343B2 and 9 further patents — semaglutide formulation and delivery
Novo Nordisk asserted ten U.S. patents covering Ozempic® (semaglutide), a GLP-1 receptor agonist approved for type 2 diabetes and weight management. The portfolio spans multiple application families — with earliest applications dating to the mid-2000s — and covers compound and formulation claims (US8129343B2, US10220155B2, US8920383B2), delivery device and pen injector claims (US9775953B2, US9687611B2), and method-of-use and combination claims across further patents. The inclusion of USRE046363E — a reissue patent — indicates Novo Nordisk has actively broadened or clarified claim scope post-grant, a common practice for commercially critical assets.
The breadth of this ten-patent assertion reflects the strategic importance of Ozempic to Novo Nordisk’s portfolio. By asserting claims across compound, formulation, device, and method layers, Novo Nordisk creates multiple independent barriers to generic entry — any one of which, if upheld, could block a competing product. For competitors and investors, this layered structure means that invalidating a subset of patents may be insufficient to clear the path to market. The semaglutide patent estate continues to attract additional ANDA challenges from multiple generic manufacturers, making monitoring of this portfolio commercially critical.
Should your product team run an FTO against the Ozempic patent estate?
Any company developing, formulating, or seeking to commercialise a semaglutide subcutaneous injectable — including ANDA filers, biosimilar-adjacent developers, or device manufacturers — should conduct a freedom-to-operate analysis against this ten-patent portfolio. The assertion of compound, formulation, device, and method claims in a single action means that design-around analysis must be conducted across all claim types. A partial clearance opinion covering only formulation claims, for example, would leave device and method exposure unaddressed.
PatSnap Eureka’s FTO Search Agent can map each of the ten asserted patents against your product specification, identify overlapping claims, and surface relevant prior art that may support invalidity arguments. Claim monitoring alerts can track any continuation applications or reissue proceedings Novo Nordisk files across this family — giving your team early visibility on shifting claim scope before a new patent issues. Given the commercial scale of the semaglutide market, proactive FTO work here is a material risk management investment.
Run a freedom-to-operate analysis on US8129343B2 to assess your product’s exposure
Run FTO in Eureka →Related ANDA patent cases in GLP-1 and semaglutide litigation
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the GLP-1 and ANDA patent landscape
A 10-patent Ozempic defence resolving by stipulation before trial offers instructive signals for generic entrants and branded manufacturers alike.
Layered patent portfolios remain the primary ANDA deterrent in biologics-adjacent markets
Novo Nordisk’s assertion of ten patents across multiple families — formulation, device, and method — illustrates the standard branded manufacturer playbook for high-value small-molecule GLP-1 drugs. Generic challengers in this space must prepare for multi-front invalidity and non-infringement arguments across all asserted patents, significantly increasing the cost and complexity of an ANDA challenge.
Stipulated dismissals before trial may signal undisclosed licensing or entry-date agreements
When a ten-patent ANDA case resolves by stipulation in under two years — well before trial — it typically suggests a commercial resolution rather than a litigated outcome. Competitors and market-entry planners should note that undisclosed licence terms or consent judgments in such cases can determine when and how a generic version actually reaches the market, without any public ruling on patent validity.
Novo v Alvogen — key questions answered
Novo Nordisk asserted ten U.S. patents: US8129343B2, US10335462B2, US11097063B2, US9775953B2, USRE046363E, US10220155B2, US9457154B2, US9132239B2, US9687611B2, and US8920383B2. The patents collectively cover semaglutide compound and formulation claims, pen injector device claims, and method-of-use claims relating to Ozempic® subcutaneous solution.
The case was closed on 10 January 2024 by a Stipulation and Order of Dismissal — a consensual termination agreed by both parties. The public record does not specify whether the dismissal was with or without prejudice. No merits ruling on patent infringement or validity was issued. The case ran for 677 days from filing to closure.
The dispute centred on Ozempic® (semaglutide) subcutaneous solution, specifically the 2 mg/1.5 ml and 4 mg/3 ml presentations at a concentration of 1.34 mg/ml. The litigation is consistent with a Paragraph IV ANDA challenge by Alvogen seeking to market a generic version of Ozempic before Novo Nordisk’s relevant patents expire.
A stipulated dismissal means both parties agreed to end the litigation without a trial on the merits. In Hatch-Waxman ANDA cases, this typically signals a negotiated commercial resolution — which may include a licence, an authorised generic agreement, or a defined future market-entry date — rather than a unilateral withdrawal. The terms of any such agreement are not disclosed in the public docket.
Delaware’s District Court is a preferred venue for Hatch-Waxman ANDA litigation due to its established case law, experienced judiciary, and efficient docket management in pharmaceutical patent disputes. Chief Judge Colm F. Connolly presided over this case. Novo Nordisk has filed multiple ANDA suits in Delaware, consistent with a deliberate enforcement strategy centred on this jurisdiction.
PatSnap Eureka searches patents and litigation data to answer instantly.